EWTX Edgewise Therapeutics
- 16.170
- +0.230+1.44%
- 16.170
- 0.0000.00%
Edgewise Therapeutics News
Express News | Edgewise Therapeutics Inc - EMA Orphan Drug Designations for Sevasemten (Edg-5506) for Treatment of Becker and Duchenne Muscular Dystrophies
Express News | Edgewise Receives EMA Orphan Drug Designations For Sevasemten For Becker And Duchenne Muscular Dystrophies
Edgewise Therapeutics Is Maintained at Outperform by RBC Capital
Edgewise Therapeutics Is Maintained at Outperform by RBC Capital
Express News | RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $32
Analysts Are Bullish on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), Edgewise Therapeutics (EWTX)
Express News | Edgewise Therapeutics Inc : RBC Raises Target Price to $32 From $28
Edgewise Therapeutics Earns 'Buy' Rating From Joseph Schwartz on Strong Clinical Data and Promising Drug Prospects
Express News | Truist Securities Maintains Buy on Edgewise Therapeutics, Maintains $25 Price Target
Analysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (EWTX), Healthequity (HQY) and Nuvation Bio (NUVB)
Express News | Wedbush Reiterates Outperform on Edgewise Therapeutics, Maintains $26 Price Target
Sector Update: Health Care Stocks Mixed Premarket Tuesday
Health care stocks were mixed premarket Tuesday with the Health Care Select Sector SPDR Fund (XLV) up 1% and the iShares Biotechnology ETF (IBB) 0.5% lower recently. UnitedHealth Group (UNH) was up mo
Edgewise Therapeutics (EWTX) Receives a Buy From Wedbush
Express News | Edgewise Therapeutics Inc - Sevasemten Was Well-Tolerated
Express News | Edgewise Therapeutics Announces Positive Two-Year Topline Results From the Arch Open Label Trial of Sevasemten (Edg-5506) in Adults With Becker Muscular Dystrophy (Becker)
Edgewise Therapeutics Announces Positive Two-Year Topline Results From the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults With Becker Muscular Dystrophy (Becker)
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive two-year topline results from the ARCH trial. ARCH is an open label, single-center study assessing safety, tolerability, impact on muscle damage biomarkers, pharmacokinetics (PK) and functional measures with sevasemten (EDG-5506) in adults with Becker.
This Edgewise Therapeutics Insider Reduced Their Stake By 98%
Insiders were net sellers of Edgewise Therapeutics, Inc.'s (NASDAQ:EWTX ) stock during the past year. That is, insiders sold more stock than they bought.
Record Levels of Funding Propel Denver-Boulder to the Top of the Life Sciences Market
The Denver-Boulder region is becoming a major hub for the life sciences industry, due to a surge in venture capital and government funding, a collaborative research environment and a booming market for lab space. The pool of qualified workers in life sciences is growing much faster in the Denver-Boulder area than the national average. "Boulder has all the elements you want in an innovation ecosystem — research universities, scientists, venture capital, and then ourselves who provide the mission-critical infrastructure," said Tim Schoen, president and CEO of BioMed Realty, which is expanding in Colorado.
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
– Presentation highlights beneficial effects of chronic EDG-7500 treatment in preventing diastolic dysfunction in an animal model of non-obstructive hypertrophic cardiomyopathy (HCM) –BOULDER, Colo.--
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Cantor Virtual Mus
Express News | RBC Capital Reiterates Outperform on Edgewise Therapeutics, Maintains $28 Price Target
Analysis
Price Target
No Data
